Mycobacterium genavense

Last updated on: 21.02.2023

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

M. genavense is characterized by extremely sparse growth, some of which may be so low in liquid cultures that it is not indicated by indicator systems. Minimal growth is also seen on agar soils and no growth is seen on egg soils. If growth is suspected, a microscopic preparation should be made from the liquid culture, even without signs of growth. In the case of M. genavense, this shows a typical picture with acid-fast, very short mycobacteria. Similarly, molecular biological detection methods may be primarily indicated when disease is suspected.

Clinical pictureThis section has been translated automatically.

M. genavense is predominantly detected in HIV patients, but isolated cases have been reported in non-HIV patients.

TherapyThis section has been translated automatically.

The optimal therapy is not known, but clarithromycin combined with RMP, an FQ, EMB, and/or SM/amikacin is recommended (Griffith DE et al 2007).

LiteratureThis section has been translated automatically.

  1. Griffith DE et al (2007) Am J Respir Crit Care Med 175: 367-416.
  2. Tribuna C et al (2015) Pulmonary Kaposi sarcoma and disseminated Mycobacterium genavense infection in an HIV-infected patient. BMJ Case Rep bcr2015211683.

Last updated on: 21.02.2023